Organon & (OGN) Stock: Buy, Sell, or Hold?
OGN - Organon & Co.
$13.64
0.01 (0.07%)
â˛
5d:
-0.94%
30d:
-0.15%
90d:
+1.41%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Aug 04, 2026
0d
Get Alerted When OGN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: OGN is fairly priced but lacks strong directional signals. At 10.4% expected growth, valuation appears stretched. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: OGN is fairly priced but lacks strong directional signals. At 10.4% expected growth, valuation appears stretched. Wait for clearer setup or better entry on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$13.67
Based on 6.2% avg growth
INTRINSIC VALUE TODAY
$8.49
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 2.8x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: OGN is currently trading at $13.64, which is considered slightly low relative to its 30-day fair value range of $13.62 to $13.77. From a valuation perspective, the stock is trading at a premium (Forward PE: 3.8) compared to its historical average (2.8). At these levels, the market is pricing in 10.4% annual earnings growth.
Technical Outlook: Technically, OGN is in a uptrend. The price is currently testing key support at $13.63. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 48/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. However, the stock is trading significantly above the average Wall Street target of $11.25. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, OGN is in a uptrend. The price is currently testing key support at $13.63. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 48/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. However, the stock is trading significantly above the average Wall Street target of $11.25. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$13.62 -
$13.77
Company Quality Score
51/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
73.3%
Protect Your Profits
Holding OGN? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (48/100)
- BULLISH: High volume confirmation
- BEARISH: Trading 17.5% above Wall St target ($11.25)
- BULLISH: Expecting earnings turnaround to 10.4% growth with -2.3% revenue growth
- WARNING: Composite score 51/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$13.62 -
$13.77
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$13.63
Resistance Level
$13.79
Current Trend
Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
3.77
Wall Street Target
$11.25
(-17.5%)
Revenue Growth (YoY)
-2.3%
Earnings Growth (YoY)
-28.3%
Profit Margin
3.4%
Valuation Premium vs History
+10.4% premium
PE vs Historical
3.8 vs 2.8
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+10.4%
(market-implied from PE analysis)
1-Year Target
$15.06
(+10%)
2-Year Target
$16.62
(+22%)
3-Year Target
$18.35
(+35%)
3-Yr Target (if PE normalizes)
(PE: 4â3)
PE COMPRESSION
$13.62
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.2, Growth: 8.4%)
$92.76
(+580%)
Base:
(SPY PE: 3.8, Growth: 8.4%)
$17.35
(+27%)
Bear:
(PE: 2.8, Growth: 8.4%)
$12.88
(-6%)
đ
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (17x PE), but valuation improves significantly next year (4x PE) as earnings recover.
Trailing PE: 17.47 | Current EPS (TTM): $0.78
Bull Case
$29.99
(+120%)
Analyst growth 100.0%, PE expands to 19.2
Base Case
$27.26
(+100%)
Market implied 100.0%, PE stable at 17.5
Bear Case
$9.27
(-32%)
Severe decline -20.0%, PE contracts to 14.9
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: September 12, 2026 10:17 PM ET
Data refreshes hourly during market hours. Next update: 11:17 PM
Data refreshes hourly during market hours. Next update: 11:17 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is OGN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LLY
Eli Lilly and Company |
STRONG BUY
31 analysts |
$1316 | 47 HOLD |
|
GILD
Gilead Sciences Inc |
BUY
30 analysts |
$157 | 44 HOLD |
|
ABBV
AbbVie Inc |
BUY
28 analysts |
$277 | 53 HOLD |
|
BIIB
Biogen Inc |
HOLD
37 analysts |
$237 | 47 HOLD |
|
AMGN
Amgen Inc |
HOLD
32 analysts |
$390 | 43 HOLD |
Advanced OGN Option Strategies
Professional options setups generated by AI based on today's OGN price and gamma walls.
